New emerging Staphylococcus aureus strains;Nouveaux Staphylocoques dorés

Revue du Praticien

Volumn 54, Issue 10, 2004, Pages 1053-1058

  Dagnra, Anoumou Yaotsé ^a   Tristan, Anne ^a   Gillet, Yves ^a,b   Étienne, Jérôme ^a  

^a INSERM   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; ENTEROTOXIN; LEUKOCIDIN; METICILLIN; PANTON VALENTINE LEUKOCIDIN; UNCLASSIFIED DRUG; VANCOMYCIN;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; COMMUNITY ACQUIRED INFECTION; HOSPITAL INFECTION; HUMAN; LETHALITY; NECROTIZING PNEUMONIA; NONHUMAN; NOSE; OSTEOMYELITIS; PNEUMONIA; REVIEW; SCARLET FEVER; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STRAIN IDENTIFICATION; TOXIC EPIDERMAL NECROLYSIS; TOXIC SHOCK SYNDROME;

DERMATITIS, EXFOLIATIVE; HUMANS; METHICILLIN RESISTANCE; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 3042798918     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol 1999; 37: 3133-40.
2. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26: 1179-81.
3. Martres P, Thibault M, Lemann F. Surveillance des bactéries multirésistantes: diminution significative du taux et de l'incidence de Staphylococcus aureus résistant à la méticilline (SARM) dans un centre hospitalier général entre 1999 et 2001. Pathol Biol (Paris) 2003; 51: 474-8.
4. Dufour P, Gillet Y, Bes M et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton Valentine leukocidin. Clin Infect Dis 2002; 35: 819-24.
5. Gillet Y, Issartel B, Vanhems P et al. Association between Staphylococcus aureus strains carrying the gene for the Panton-Valentine leukocidin and highly-lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359: 753-9.
6. Gravet A, Couppie P, Meunier O et al. Staphylococcus aureus isolated in cases of impetigo produces both epidermolysin A or B and LukE-LukD in 78% of 131 retrospective and prospective cases. J Clin Microbiol 2001; 39: 4349-56.
7. Lina G, Piemont Y, Godail-Gamot F et al. Involvement of Panton Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128-32.
8. Guarner J, Shieh WJ, Dawson J et al. Immunohistochemical and in situ hybridization studies of influenza A virus infection in human lungs. Am J Clin Pathol 2000; 114: 227-33.
9. Mongodin E, Bajolet O, Cutrona J et al. Fibronectin-binding proteins of Staphylococcus aureus are involved in adherence to human airway epithelium. Infect Immun 2002; 70: 620-30.
10. Bernardo X, Pakulat N, Fleer S et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48: 544-6.
11. Gemmell CG, Ford CW. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 2002; 50: 665-72.
12. Gauduchon V, Cozon G, Vandenesch F et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004; 189: 346-53.
13. Lina G, Vandenesch F, Etienne J. Les syndromes toxiques staphylococciques pédiatriques de 1998 à 2000. Données de Centre national de référence des toxémies à staphylocoques. Arch Pediatr 2001; 8 (Suppl. 4): 769s-775s.
14. Parsonnet J. Case definition of staphylococcal TSS: a proposed revision incorporating laboratory findings. In: Arbuthnott J, Furman B (eds). European Conference on Toxic Shock Syndrome. International Congress and Symposium Series 229. New York, N. Y: Royal Society of Medicine Press Ltd; 1998: 15.
15. Russell NE, Pachorek RE. Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes. Ann Pharmacother 2000; 34: 936-9.
16. Coyle EA. Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2003; 23: 638-42.
17. Wong GW, Oppenheimer SJ, Evans RM, Leung SS, Cheng JC. Pyomyositis and staphylococcal scalded skin syndrome. Acta Paediatr 1993; 82: 113-5.
18. Raymond J, Bingen E, Brahimi N et al. Staphylococcal scalded skin syndrome in a neonate. Eur J Clin Microbiol Infect Dis 1997; 16: 453-4.
19. Jarraud S, Lina G, Vandenesch F, Etienne J. Épidémiologie des infections toxiniques à staphylocoques dorés. Ann Fr Anesth Reanim 2002; 21: 370-4.
20. Hanakawa Y, Schechter NM, Lin C et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002; 110: 53-60.
21. Liassine H, Auckenthaler R, Descombes MC, Bes M, Vandenesch F, Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton Valentine leukocidin or exfoliative toxin genes. J Clin Microbiol 2004; 42: 825-8.
22. Saravolatz LD, Pohlod DJ, Arking LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med 1982; 97: 325-9.
23. de Neeling AJ, van Leeuwen TJ, Schouls LM et al. Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989-1995. J Antimicrob Chemother 1998; 41: 93-101.
24. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-84.
25. rd et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37: 1313-9.
26. Anonymous. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. JAMA 1999; 282: 1123-5.
27. Groom AV, Wolsey DH, Naimi TS et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001; 286: 1201-5.
28. Collignon P, Gosbell I, Vickery A, Nimmo G, Stylianopoulos T, Gottlieb T. Community-acquired meticillin-resistant Staphylococcus aureus in Australia. Australian Group on Antimicrobial Resistance. Lancet 1998; 352: 145-6.
29. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9: 978-84.
30. Cohen PR, Kurzrock R. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol 2004; 50: 277-80.
31. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003; 37: 933-8.